Roche’s giredestrant was approved by the US FDA for the treatment of ESR1-mutated, ER+, HER2- breast cancer, joining three other oral SERDs on the market.
Roche has a new drug approved for breast cancer (Shutterstock) Key TakeawaysRoche’s Wilserdly (giredestrant) is the fourth next-generation oral selective estrogen receptor degrader (SERD) to reach the market for ESR1-mutated, ER+, HER2- advanced or metastatic breast cancer after endocrine therapy.
Roche’s Wilserdly (giredestrant) was approved by the US Food and Drug Administration as the fourth next-generation oral selective estrogen receptor…